Contineum Therapeutics Reports Topline Data From Phase 2 VISTA Trial Evaluating PIPE-307 in Relapsing-Remitting Multiple Sclerosis Contineum Therapeutics, Inc. (NASDAQ: CTNM) (“Contineum” or the “Company”), a clinical-stage biopharmaceutical organization advancing differentiated therapies across neuroscience, inflammation, and immunology (NI&I), announced the…
Phase 1 Trial Reveals Promising Early Activity for Tinostamustine in Glioblastoma Purdue Pharma L.P. (“Purdue”) has announced encouraging preliminary data from its ongoing Phase 1 clinical study evaluating tinostamustine in patients with MGMT promoter-unmethylated (uMGMT) glioblastoma (GBM), an especially aggressive…
Parse Biosciences Unveils Breakthrough FFPE-Compatible Barcoding Technology, Enabling Whole-Transcriptome Single-Cell Analysis from Archival Tissues Parse Biosciences, a global leader in scalable and accessible single-cell sequencing technologies, has announced a transformative advancement that stands to reshape how researchers analyze archived biological…
Single-tablet regimen shows non-inferior efficacy and strong safety in virologically suppressed adults with HIV-1. Gilead Sciences, Inc. (NASDAQ: GILD) has announced encouraging topline results from its Phase 3 ARTISTRY-1 clinical trial, marking an important milestone in the company’s ongoing efforts…
Samsung Epis Holdings Launches Epis NexLab to Pioneer Next-Generation Biotech Platforms and Drive Global Innovation Samsung Epis Holdings Co., Ltd. has officially announced the establishment of Epis NexLab Co., Ltd., a wholly owned subsidiary dedicated to advancing next-generation biotechnology platforms.…
City Therapeutics Submits Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic Targeting Factor XI for the Treatment of Thromboembolic Diseases City Therapeutics, Inc., a pioneering biopharmaceutical company focused on advancing the field of RNA interference (RNAi)-based medicine, today announced…
AstraZeneca’s FASENRA Demonstrates Statistically Significant Clinical Benefit in Phase III NATRON Trial for Hypereosinophilic Syndrome AstraZeneca has announced positive full results from its pivotal Phase III NATRON clinical trial evaluating FASENRA (benralizumab) as a therapeutic option for patients living with…
ONDEX Automation Acquires PlantOPS Consulting, Expands MES and Life Sciences Capabilities ONDEX Automation has announced the acquisition of PlantOPS Consulting, a well-established specialist in Manufacturing Execution System (MES) consulting and implementation for pharmaceutical, biotechnology, and medical technology companies. The transaction…
NMDP and CIBMTR to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 2025 NMDP℠, a leading global nonprofit dedicated to advancing cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) announced that they…
Zetagen Therapeutics Announces Presentation of Promising Phase 2a Data Demonstrating Complete Responses in Metastatic Breast Cancer Bone Lesions at 2025 SABCS Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company developing innovative, targeted therapies for both primary and metastatic breast cancer,…
Vistagen Completes Phase 3 PALISADE-3 Trial Evaluating Fasedienol for Acute Treatment of Social Anxiety Disorder Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company advancing neuroscience through innovative nose-to-brain therapeutics, announced the completion of patient participation in the randomized, double-blind, placebo-controlled…
CHMP Recommends Saphnelo Subcutaneous Administration for SLE in the EU, Offering Convenient Self-Administration Option AstraZeneca has announced that its fully human monoclonal antibody Saphnelo (anifrolumab) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)…
